论文部分内容阅读
目的分析Ⅲ期贲门腺癌术后抗幽门螺杆菌(helicobacter pylori,Hp)治疗与预后的相关性,为贲门癌术后治疗提供依据。方法选取95例贲门中低分化腺癌术后Hp检测阳性患者为研究对象,按术后是否接受“抗Hp”的治疗分为观察组(接受“抗Hp”治疗;n=48)和对照组(未接受“抗Hp”治疗;n=47),并对患者随访3年。结果观察组有40例患者抗Hp治疗有效。观察组和对照组患者3年生存率分别为25%和23.4%(P=0.053),吻合口复发率分别为10%和21.3%(P<0.05)。但两组患者肝、肺、骨转移的发生率均无统计学意义(P>0.05)。结论对贲门腺癌术后Hp检测阳性患者进行抗Hp治疗可以有效降低吻合口肿瘤的复发率。
Objective To analyze the correlation between postoperative anti-Helicobacter pylori (Hp) treatment and prognosis in stage Ⅲ gastric cardia adenocarcinoma, and to provide evidence for postoperative treatment of gastric cardia cancer. Methods Ninety-five patients with poorly differentiated adenocarcinoma of the cardia were enrolled in this study. The patients were divided into observation group (receiving “anti-Hp” treatment and n = 48 ) And control group (did not receive “anti-Hp” treatment; n = 47) and were followed up for 3 years. Results In the observation group, 40 patients were treated with anti-Hp therapy. The 3-year survival rate was 25% in the observation group and 23.4% in the control group (P = 0.053). The recurrence rates of the anastomotic stoma were 10% and 21.3%, respectively (P <0.05). However, the incidence of liver, lung and bone metastases between the two groups was not statistically significant (P> 0.05). Conclusion Anti-Hp therapy can effectively reduce the recurrence rate of anastomotic tumors in patients with positive gastric cardia cancer after Hp detection.